SA
VRTX icon

Strategic Advocates’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Advocates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$454 – 608
2025
Q4 		$454 Buy
+1
New +$431 ﹤0.01% 551
2024
Q2 		– Sell
-5,558
Closed -$2.32M – 139
2024
Q1 		$2.32M Buy
+5,558
New +$2.35M 0.89% 26

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Strategic Advocates's VRTX Position: Q1 2026 in Review

Strategic Advocates sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 1 share — an estimated $454 sold.

Strategic Advocates first reported a position in VRTX in Q1 2024 and held it in 2 quarters. The position peaked at $2.32M in Q1 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Strategic Advocates reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 1 Vertex Pharmaceuticals share in Q1 2026, an estimated $454.
  • Strategic Advocates first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Strategic Advocates's Vertex Pharmaceuticals position peaked at $2.32M in Q1 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.